LncRNA NEAT1 regulate diffuse large B-cell lymphoma by targeting miR-495-3p/PD-L1 axis

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a prevalent lymphoid malignancy.
• Long non-coding RNAs (lncRNAs) are implicated in cancer development, including DLBCL.
• This research investigates the specific role of NEAT1 in DLBCL pathogenesis.

Purpose of the Study:

• To elucidate the function of NEAT1 in DLBCL.
• To identify the molecular mechanisms underlying NEAT1's role in DLBCL.
• To explore NEAT1 as a potential therapeutic target or biomarker for DLBCL.

Main Methods:

• Quantitative polymerase chain reaction (RT-qPCR) for mRNA expression analysis.
• Bioinformatic prediction (StarBase, TargetScan) and experimental validation (Dual Luciferase Reporter Assay, RNA pull-down) of targeting relationships.
• Cell viability (CCK-8), apoptosis (flow cytometry), cytotoxicity (LDH release), and protein expression (Western blotting) assays.

Main Results:

• NEAT1 expression is elevated in DLBCL patients and promotes tumor cell viability and proliferation.
• NEAT1 directly targets and downregulates miR-495-3p, a tumor suppressor.
• NEAT1 acts as a molecular sponge for miR-495-3p, leading to the upregulation of PD-L1, a key immune checkpoint molecule.

Conclusions:

• A novel NEAT1/miR-495-3p/PD-L1 signaling axis is identified as a regulator of DLBCL progression.
• NEAT1 inhibition suppresses DLBCL malignancy by restoring miR-495-3p levels and reducing PD-L1 expression.
• NEAT1 represents a promising diagnostic biomarker and therapeutic target for DLBCL.